Q3 2018 results demonstrated continued progress – In line with market expectations, sales expanded by 10.1%, while gross margins raised to 47.3% (46.9%), delivering a 15.6% improvement in net profits (BDT603m; £5.4m).
09 Jul 2018
Q3 2018 Company Update – Progress Sustained
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Q3 2018 Company Update – Progress Sustained
Beximco Pharmaceuticals Limited Sponsored GDR RegS (BXP:LON) | 39.0 0 0.0% | Mkt Cap: 174.0m
- Published:
09 Jul 2018 -
Author:
Barry Gibb -
Pages:
17
Q3 2018 results demonstrated continued progress – In line with market expectations, sales expanded by 10.1%, while gross margins raised to 47.3% (46.9%), delivering a 15.6% improvement in net profits (BDT603m; £5.4m).